HCG reports robust Q3 & 9M FY26 growth, strengthening its lead in Indian oncology

HCG clinicians contributing to one of the largest bodies of oncology research from India

ALX Oncology’s evorpacept shows promise in HER2-positive breast cancer

The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy

Lupin launches Dasatinib tablets in US, eyes $930 million oncology market

AVEO Oncology doses first patient in pioneering AML clinical trial

The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy

BioNTech maps pivotal oncology milestones for 2026

BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company

Amgen snaps up UK biotech Dark Blue Therapeutics in up to $840m oncology deal

The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation

Biocon Biologics to introduce three new oncology biosimilars, eyes $75 billion market opportunity

The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies

FDA nods spotlight precision oncology platforms as market surges towards $212 billion by 2034

The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034

Kelun-Biotech and Crescent Biopharma forge strategic oncology partnership

The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination

Takeda seals $1.2 billion oncology deal with Innovent Biologics

Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent